Clinical Report: Meta-Analysis of Adjuvant Immune Checkpoint Inhibitors
Overview
This meta-analysis evaluates the efficacy of adjuvant immune checkpoint inhibitors (ICIs) across various solid tumors. The analysis included 21 randomized controlled trials with a total of 17,446 patients.
Background
Adjuvant immunotherapy has become a critical component in the treatment of solid tumors, aiming to reduce recurrence risk and improve long-term survival. Understanding their efficacy is essential for optimizing treatment strategies in oncology.
Data Highlights
Outcome
Hazard Ratio (HR)
95% Confidence Interval (CI)
p-value
DFS/RFS/PFS
0.74
0.68–0.82
<0.0001
OS
0.84
0.78–0.90
<0.0001
Key Findings
Adjuvant ICIs significantly improved DFS/RFS/PFS with a pooled HR of 0.74.
Overall survival (OS) was also significantly improved with a pooled HR of 0.84.
DFS/RFS benefits were observed in melanoma (HR 0.65), urothelial carcinoma (HR 0.78), renal cell carcinoma (HR 0.84), and NSCLC (HR 0.87).
CTLA-4, anti–PD-1, and anti–PD-L1 inhibitors showed significant DFS/RFS benefits with HRs of 0.77, 0.69, and 0.89, respectively.
Statistically significant OS benefits were noted in melanoma (HR 0.76) and urothelial carcinoma (HR 0.85).
Exploratory meta-regression indicated a significant association between ICI class and treatment effect (QM p = 0.0183).
Clinical Implications
The findings support the use of adjuvant ICIs in various solid tumors, highlighting their role in improving DFS and OS. Clinicians should consider these results when discussing treatment options with patients, particularly in high-risk settings.
Conclusion
Adjuvant immune checkpoint inhibitors demonstrate significant efficacy in improving outcomes for patients with solid tumors.
The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.
